TrialLancet (London, England)2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Matthew S Davids et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.